Develops biological drugs for central nervous system disorders. Researches and develops innovative antibodies to address unmet medical needs. Now — the numbers.
This is an established company with proven profits.
Average growth of 205% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $220.9M would still be left in the vault — a solid cushion for hard times.
The market pays 31.1× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The net profit margin is 51% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 205% a year on average.
There is $225.4M in the vault; even if every debt were paid off, $220.9M would remain.
The price action doesn’t yet back an upward turn. Council score: 0/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.